Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson's Q1 Revenues Edge up Slightly

NEW YORK (GenomeWeb News) – Becton Dickinson reported today that its first-quarter 2009 revenues rose nearly 2 percent to $1.73 billion from $1.71 billion in the comparable period of 2008.

Revenues for its BD Diagnostics segment increased 3 percent to $540 million from $523 million year over year, including a negative impact of 3 percent from foreign currency translation. Its BD Biosciences segment brought in revenues of $303 million, up 11 percent from revenues of $274 million in the first quarter of 2008, and including a 1 percent benefit from currency translation. Sales for its BD Medical segment dropped 2 percent to $891 million from $909 million, including a 4 percent negative impact from currency translation.

BD's net income climbed 15 percent to $312.1 million, or $1.26 per share, from $271.5 million, or $1.07 per share, year over year.

The firm's R&D spending increased around 7 percent to $97.5 million from $91.5 million, and its SG&A expenses dropped 3 percent to $409.9 million from $421.7 million.

BD said that it expects its full-year 2009 earnings per share to increase around 9 percent to 11 percent over its EPS of $4.46 for fiscal 2008.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.